Apimeds Pharmaceuticals US, Inc
New York Stock Exchange AmericanRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Apimeds Pharmaceuticals US, Inc. operates as a clinical-stage biopharmaceutical enterprise within the United States. The company is dedicated to the research, development, and eventual commercialization of Apitox, a unique intradermally administered compound derived from purified honeybee venom. This investigational biologic is primarily being advanced through Phase III clinical trials for managing inflammation and pain associated with knee osteoarthritis. Additionally, Apimeds is conducting non-registered corporate sponsorship studies to explore its potential applications for multiple sclerosis. The company, which commenced operations in 2020, recently completed its Initial Public Offering in May 2025, with shares now trading on the NYSE American under the ticker "APUS." Apimeds Pharmaceuticals US is located in Matawan, New Jersey, and operates with a licensing agreement for Apitox from Apimeds Korea, where a similar product has been in use.
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm
APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm
Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy
Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon's Lundquist College of Business
Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
U.S. IPO Weekly Recap: Sizable Insurance IPOs Deliver Solid Trading